Sign inJoin waitlistJoin the waitlist

Megan Baumgart

Fellowship Program Director · University of Rochester Medicine

Credentials: · · · · ·

History

University of Rochester Medicine Fellowship
Present
University of Rochester Medicine
Present
University of Rochester
Present

Hematology and Medical Oncology
University of Rochester Medicine
2014–2017
fellowship in Medical
2011–2014
Yale-New Haven Hospital
2007–2010
Internal Medicine
Rhode Island Hospital/Brown University Health
2007–2008
Albany Medical College
2003–2007

Research

Randomized Trial of Afatinib Plus Cetuximab Versus Afatinib Alone for First-Line Treatment of EGFR-Mutant Non-Small-Cell Lung Cancer: Final Results From SWOG S1403
Journal of Clinical Oncology · 2020 · 57 citations
N-acylglycine amidation: implications for the biosynthesis of fatty acid primary amides
Biochemistry · 1999 · 45 citations
A Phase Ib/II Study of Pepinemab in Combination with Avelumab in Advanced Non-Small Cell Lung Cancer
Clinical Cancer Research · 2021 · 25 citations

Deborah Mulford
2 papers
Jane Liesveld
2 papers
Jason Mendler
2 papers
Kah Loh
2 papers
Marissa LoCastro
2 papers · 1 as a resident
NG
Nashat Gabrail
2 papers
Ronald Maggiore
2 papers · 2 as a fellow
Scott Gettinger
2 papers
Aaron Mansfield
1 paper
AA
Alexander Asser
1 paper
AS
Alexander Spira
1 paper
Balazs Halmos
1 paper

Clinical trials

Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial
Principal investigator · Recruiting · Phase 3
National Cancer Institute (NCI)
2024–2039
Study of Pembrolizumab and Single Agent Chemotherapy as First Line Treatment for Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer With Eastern Cooperative Oncology Group (ECOG) Performance Status of 2
Principal investigator · Recruiting · Phase 1
University of Rochester
2020–2028
Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study
Site PI · Recruiting · Phase 2
SWOG Cancer Research Network
2025–2029
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
Site PI · Recruiting · Phase 2, Phase 3
SWOG Cancer Research Network
2025–2028